Sign Out
3.75 mg & 11.25 mg: Prostate cancer: Metastatic prostate cancer; Locally advanced prostate cancer, as an alternative to surgical castration; As an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer; As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.
Endometriosis at genital and extragenital localization (From stage I to stage IV).
Premenopausal breast cancer.
3.75 mg: Uterine Fibroids (Leiomyomata); Central precocious puberty (CPP).
11.25 mg: Symptomatic laparoscopically confirmed endometriosis, when suppression of ovarian hormone production is indicated, provided the disease does not primarily require surgery.
Preoperative flattening of the endometrium before planned operative hysteroscopic intervention, e.g. endometrium ablation or resection.
Symptomatic Uterine Fibroids (Leiomyomata), when suppression of ovarian hormone production is indicated, as a preoperative measure for the volume reduction of individual fibroids in fibroid nucleation or hysterectomy.
Treatment of central precocious puberty (girls under 9 years of age, boys under 10 years of age).
30 mg: Advanced Prostate Cancer.
Continue with Google